Abstract
We recruited four aquaporin-4 seropositive optic neuritis patients (five eyes) who received glucocorticoid treatment and underwent optical coherence tomography examination. Baseline medians of the macular ganglion cell layer plus inner plexiform layer (mGCIPL) thickness and volume for the eye of interest were 79.67 µm (73.664 ± 18.497 µm) and 0.58 mm3 (0.534 ± 0.134 mm3), respectively. At 2 months, the medians of the mGCIPL thickness and volume were 60.00 µm (51.576 ± 12.611 µm) and 0.44 mm3 (0.376 ± 0.091 mm3), respectively. At 6 months, the medians of the mGCIPL thickness and volume were 59.55 µm (46.288 ± 11.876 µm) and 0.44 mm3 (0.336 ± 0.084 mm3), respectively. Sample size estimate was achieved using two methods based on the mGCIPL thickness and volume data, with five effect sizes considered. The estimate based on the mGCIPL volume showed that 206 patients were needed at the 6-month follow-up; the power was 80% and effect size was 20%. In conclusion, this study detected retinal damage in aquaporin-4 seropositive optic neuritis patients by optical coherence tomography, and estimated the sample size for two-sample parallel designed clinical trials using two methods.
1 Introduction
Optic neuritis (ON) is an autoimmune inflammatory demyelinating disease of the optic nerve that primarily affects young people aged 18–45 years, frequently resulting in permanent visual dysfunction [1]. Aquaporin-4 (AQP4) immunoglobulin G (IgG) seropositive ON patients suffer more severe vision loss and exhibit poor vision recovery, compared to AQP4 IgG seronegative ON patients [2]. Retinal ganglion cell (RGC) loss as a main feature of the irreversible retinal injury has been shown in the eyes of ON patients [3]. More than 50% of the macular cells are RGCs, and thinning of the macular layers, which are composed of the retinal nerve fiber layer (RNFL) and the ganglion cell layer plus inner plexiform layer (GCIPL), was observed in ON and ischemic optic neuropathy [4,5,6]. Optical coherence tomography (OCT) can be applied to non-invasively measure the RNFL and GCIPL thicknesses in neurological diseases [7]. Considering that the distribution of the RNFL exhibits distinct differences between individuals, the distribution of the GCIPL is relatively stable [8], thus, measuring the macular GCIPL (mGCIPL) in ON patients is more meaningful.
The dominant view is that glucocorticoid (GC) treatment of ON does not improve the patients’ final visual acuity, and developing optic nerve protection drugs is one of the most important objectives of current research. Performing randomized controlled trials is one of the most important methods to evaluate the efficacy and safety of new interventions. To ensure reliable results, avoid abusing resources and minimize damage, sample sizes of randomized controlled trials require estimation. However, previous studies estimating the sample size for ON did not distinguish between AQP4-IgG seropositive and seronegative patients [9,10]. Therefore, in this study, we aim to estimate the sample size for two-sample parallel designed clinical trials based on the mGCIPL volume and thickness in AQP4-IgG seropositive ON patients, which will provide a reference for the future study of neuroprotective or myelin regenerative agents.
2 Participants and methods
2.1 Participants
Four eligible patients (one male and three females, median age 42 years, range 22–51 years, Table 1) were recruited from the First Affiliated Hospital of Guangxi Medical University from January 2017 to January 2019. The median time of the first OCT examination after the onset of symptoms was 12 days, ranging from 10 to 16 days. The patient inclusion criteria were: (1) First episode of acute ON. (2) AQP4-IgG seropositive. (3) Chinese patients aged 18–60 years without gender limitation. (4) Best-corrected visual acuity of the eye of interest ≤0.8. Exclusion criteria included any of the following: (1) Patients with pre-existing multiple sclerosis (MS) or neuromyelitis optica. (2) Refractive media opacity, hyperopia >5 diopters, myopia <−5 diopters or astigmatism >3 diopters. (3) Active tuberculosis, hepatitis, renal insufficiency, uncontrolled hypertension, diabetes mellitus, HIV or syphilis infection or any other conditions potentially interfering with the treatment trial. (4) Other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis and other diseases). (5) Existing other retinal or optic nerve diseases. The flow diagram of participants is shown in Figure 1.
Characteristics of eyes included
| Case | laterality | Baseline | 2 months | 6 months | |||
|---|---|---|---|---|---|---|---|
| Mean of mGCIPL volume (mm3) | Mean of mGCIPL thickness (μm) | Mean of mGCIPL volume (mm3) | Mean of mGCIPL thickness (μm) | Mean of mGCIPL volume (mm3) | Mean of mGCIPL thickness (μm) | ||
| 1 | OD | 0.62 | 87.77 | 0.46 | 64.11 | 0.37 | 53.44 |
| 2 | OD | 0.30 | 41.66 | 0.25 | 33.77 | 0.25 | 32.55 |
| 3 | OS | 0.58 | 79.67 | 0.44 | 60.00 | 0.44 | 59.55 |
| 4 | OD | 0.55 | 75.22 | 0.31 | 43.44 | 0.25 | 35.01 |
| 5 | OS | 0.62 | 84.00 | 0.42 | 56.56 | 0.37 | 50.89 |
OD represents for right eye and OS represents for left eye.
Flow diagram of participants.
-
Informed consent: Informed consent has been obtained from all individuals included in this study.
-
Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the ethical review committee of First Affiliated Hospital of Guangxi Medical University (No. 2017(KY-E-068)).
2.2 AQP4-IgG test and ophthalmologic examinations
The serum was tested for AQP4-IgG by a cell-based assay. Every patient underwent ophthalmologic examinations and were given methylprednisolone intravenously for 3–5 days, the dosage subsequently being gradually reduced. The eye examination at onset and at 2- and 6-month follow-up included the best-corrected visual acuity, pattern visual evoked potentials and visual field examination.
2.3 OCT examinations and analyses
Retinal images were obtained on the day of hospitalization by Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany), which provides 40,000 A-scans per second with a 5.7 µm digital axial resolution. The following retinal layers were produced: (1) RNFL; (2) mGCIPL; (3) inner nuclear layer and outer plexiform layer; and (4) outer nuclear layer (including inner and outer photoreceptor segments). Briefly, macular data scans were obtained with Macular Cube 512 × 128 protocols. The software (Spectralis OCT) automatically generates thickness maps corresponding to the foveal area and the paracentral mGCIPL. The software (Spectralis OCT) also identifies the inner limiting membrane and the inner boundary of the retinal pigment epithelium within the 6 mm × 6 mm × 1.9 mm volume cube scan to determine the mGCIPL volume. The images were obtained of the patients with dilated pupils (Compound Tropicamide Eye Drops: 0.5% tropicamide mixed with 0.5% deoxyepinephrine hydrochloride in a 1:1 ratio) by the same trained technician. All images were reviewed by a trained physician to ensure appropriate scan quality and correct segmentation. If the segmentation was incorrect, a manual correction was performed.
2.4 Statistical analyses and sample size estimation
All statistical analyses and sample size estimation were completed using the R program (R for Mac OS X GUI 3.4.3). The median and mean values and standard deviation (SD) were obtained to describe the data distribution. Differences were considered to be statistically significant for P-values < 0.05. The sample size estimate was achieved using the following equations:
where κ is the matching ratio; σ is the SD; ϕ is the standard normal distribution function; α is the Type I error (0.05); β is the Type II error, and 1 − β is the power (80, 90, and 95%).
Each patient underwent OCT examination on certain dates. The sample size was estimated using the following two methods:
Method A: Comparison of the follow-up of the affected eye mGCIPL thickness and volume. The mean and SD values of the mGCIPL volume and thickness at the follow-up of the affected eye were required. Assuming that the protective effects of the test drug on the mGCIPL thickness and volume were 20, 30, 40, 50 and 60% at 2 and 6 months, the mean values for the test drug at 2 and 6 months were calculated according to the different effect sizes of therapeutic effects. Subsequently, the sample size was estimated.
Method B: Comparison of the difference between the follow-up and baseline of the affected eye mGCIPL volume and thickness. The SD values of this difference were required. The difference was obtained from the baseline value minus the follow-up value. The other parts were consistent with Method A.
3 Results
3.1 OCT and ophthalmic examinations
We applied the OCT technique to detect the patients’ mGCIPL thickness and volume at the time of onset and 2 and 6 months after onset, which are shown in Figures 2 and 3 and Table 1. The median mGCIPL thickness for the eye of interest at the baseline was 79.67 µm (73.664 ± 18.497 µm, range 41.66–87.77 µm) and the median mGCIPL volume was 0.58 mm3 (0.534 ± 0.134 mm3, range 0.30–0.62 mm3). At 2 months, the median mGCIPL thickness was 60.00 µm (51.576 ± 12.611 µm, range 33.77–64.11 µm) and the median mGCIPL volume was 0.44 mm3 (0.376 ± 0.091 mm3, range 0.25–0.46 mm3). At 6 months, the median mGCIPL thickness was 59.55 µm (46.288 ± 11.876 µm, range 32.55–59.55 µm) and the median mGCIPL volume was 0.44 mm3 (0.336 ± 0.084 mm3, range 0.25–0.44 mm3). In addition, the visual acuity of the affected eyes at the time of onset and 2 and 6 months after onset are illustrated in Figure 4.
Results of OCT examination. Panels (a–e) indicate the first to the fifth eyes, respectively. Columns 1, 3 and 5 for the mGCL at baseline and 2 and 6 months, respectively. Columns 2, 4 and 6 for mIPL at baseline and 2 and 6 months, respectively. (mGCL = macular ganglion cell layer; mIPL = macular inner plexiform layer).
Results of OCT examination: (a) mGCIPL thickness of the affected eye; (b) mGCIPL volume of the affected eye; and (c) RNFL thickness of the affected eye.
Visual acuity of the affected eye.
3.2 Sample size estimation
The sample size was estimated based on the mGCIPL thickness and volume at 2 and 6 months. The detailed results are shown in Table 2.
Estimation of sample size for mGCIPL volume and thickness
| Effect size (%) | 80% power | 90% power | 95% power | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | A | B | A | B | |||||||
| Volume | Thickness | Volume | Thickness | Volume | Thickness | Volume | Thickness | Volume | Thickness | Volume | Thickness | |
| 2 months | ||||||||||||
| 20 | 262 | 256 | 160 | 134 | 350 | 342 | 214 | 180 | 434 | 424 | 264 | 222 |
| 30 | 118 | 114 | 72 | 60 | 156 | 152 | 96 | 80 | 194 | 188 | 118 | 100 |
| 40 | 66 | 64 | 40 | 34 | 88 | 86 | 54 | 46 | 110 | 106 | 66 | 56 |
| 50 | 42 | 42 | 26 | 22 | 56 | 54 | 38 | 30 | 70 | 68 | 44 | 36 |
| 60 | 30 | 30 | 18 | 16 | 40 | 40 | 24 | 20 | 50 | 48 | 30 | 26 |
| 6 months | ||||||||||||
| 20 | 140 | 148 | 206 | 166 | 188 | 198 | 274 | 222 | 232 | 244 | 340 | 274 |
| 30 | 62 | 66 | 92 | 74 | 84 | 88 | 124 | 100 | 104 | 110 | 152 | 122 |
| 40 | 38 | 38 | 52 | 42 | 52 | 50 | 70 | 56 | 62 | 62 | 86 | 70 |
| 50 | 24 | 24 | 34 | 28 | 30 | 32 | 44 | 36 | 38 | 40 | 56 | 44 |
| 60 | 16 | 18 | 24 | 20 | 22 | 22 | 32 | 26 | 26 | 28 | 38 | 32 |
Effect size: percent decrease in mGCIPL volume and thickness comparing neuroprotective treatment vs GCs arm. A: Method A, comparison of follow-up affected eye mGCIPL volume and thickness. The mean and standard deviation values of the mGCIPL volume and thickness of follow-up affected eye were required. Assuming that the protective effects of test drug on mGCIPL volume and thickness were 20, 30, 40, 50 and 60% at 2 and 6 months. The mean values for test drug at 2 and 6 months were calculated according to the different effect sizes of therapeutic effects. Then, the sample size was estimated. B: Method B, comparison of difference between follow-up and baseline affected eye mGCIPL volume and thickness. The standard deviation values of this difference were required. The follow-up affected eye in this method was adjusted for baseline affected eye. The other parts were consistent with Method A.
As an example:
We aimed to compare a form of neuroprotective drug with GCs regarding the curative effect at 2 months using Method A. Our study showed that in GC treatment, the mean value of the mGCIPL volume at 2 months was 0.376 mm3 with an SD of 0.091 mm3. We needed to determine the sample size to evaluate the difference between two different groups treated by GCs with placebo and GCs with neuroprotective drug, considering an alpha error of 5% and a beta error of 20%. We assumed that the effect size was 20%, and substituted the values of the means, deviation and alpha and delta errors of the test and the obtained data are shown in Figure 5. Therefore, we needed 262 individuals with AQP4-IgG seropositive ON (131 per arm) to detect the difference between the test drug and GCs. Furthermore, the sample size can be extended according to the estimated loss rate.
R code for the example of sample size estimate.
4 Discussion
Previous research suggested that optic nerve demyelination caused by clinical or subclinical ON results in retrograde degeneration of optic nerve axons, thus leading to RNFL and mGCIPL thinning [11,12]. In this study, we evaluated the changes in the mGCIPL and RNFL from the time of onset to 2 and 6 months after onset of AQP4-IgG seropositive ON patients. As expected, compared with the baseline, both the mGCIPL thickness and volume underwent a clear decline at 2 months after ON onset, whereas no differences were observed between 2 and 6 months, which were similar to the findings reported by Fard et al. [13]. Also, Kupersmith et al. [14] observed mGCIPL thinning at 1 month after ON onset. Even in patients with unilateral disease, the mGCIPL thickness in the contralateral unaffected eyes was gradually reduced during follow-up [15]. However, RNFL thickness measurement could be affected by various conditions, such as varying characteristics of the study subjects and different statistical methods. Fard et al. [13] found that the RNFL thickness underwent a clear decline at 1 month after ON onset. Saidha et al. [16] found a subtype of MS patients with a predominant macular thinning phenotype but normal RNFL thickness. Herein, we found that the RNFL thickness exhibited no obvious difference at the time of onset or 2 or 6 months after ON onset, which may also be explained by the small sample in addition to individual differences. Additionally, it has been found that vascular-mediated optic neuropathy can cause nerve fiber and ganglion cell damage in the inner retina in glaucoma and ischemic optic neuropathy [17]. Kwapong et al. [18] found that decreased macular microvessel density was positively correlated with RGC loss. Therefore, the measurement of mGCIPL thickness and volume is a more specific indicator of RGC loss in ON patients.
The mGCIPL thickness was associated with visual field recovery [7]. Fard et al. [13] also revealed correlations between GCIPL thinning at 1 month and baseline visual acuity, which was in agreement with the association between GCIPL thickness and visual function in MS patients reported by Walter et al. [19]. In the present study, we also assessed the visual acuity of AQP4-IgG seropositive ON patients at the time of onset and at 2 and 6 months after onset. Compared with the baseline, visual acuity underwent clear elevation at 2 months after ON onset, whereas no significant difference was observed between 2 and 6 months, which may be largely due to GC treatment.
The sample size estimation will be helpful for the clinical trials of AQP4-IgG seropositive ON patients. To our knowledge, previous studies have estimated the sample size based on mGCIPL thickness after acute ON [9]; however, AQP4-IgG seropositive and seronegative patients were not distinguished. The etiology and degree of injury in AQP4-IgG seropositive ON patients were different from AQP4-IgG seronegative ON patients, hence AQP4-IgG seropositive patients suffered greater visual impairment, a higher clinical recurrence rate and more clinical demyelinating attacks [20,21]. Additionally, in most previous studies, primary manual analysis of segmented macular layers reduced the repeatability and accuracy of OCT measurements [22]. In the present study, the use of automated mGCIPL volume and thickness measurements was preferred to minimize measurement errors. Although OCT detection alone cannot directly diagnose ON, it can effectively and accurately follow up this disease and may be helpful to predict the prognosis for vision. However, a limitation of this study was the small sample size. Despite this, potential bias could be balanced by the small SD values.
5 Conclusion
This study estimated the sample size for two-sample parallel designed clinical trials in AQP4-IgG seropositive ON patients via OCT-measured mGCIPL thickness and volume, which may be helpful for clinical studies in AQP4-IgG seropositive ON patients.
-
Funding information: This study received funding from the Joint Construction Project of Henan Medical Science and Technology (LHGJ20220370) and the Natural Science Foundation of Henan (232300420237).
-
Author contributions: S.L. designed the study and revised the article; S.L., C.M., and Y.D. performed the study; Y.D. drafted the article. All authors read and approved the article.
-
Conflict of interest: Authors state no conflict of interest.
-
Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
[1] Zhou H, Xu Q, Zhao S, Wang W, Wang J, Chen Z, et al. Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients. Br J Ophthalmol. 2017;101(12):1720–4.Search in Google Scholar
[2] Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for 4 years in the N-MOmentum trial. Mult Scler J. 2022;28(6):925–32.Search in Google Scholar
[3] Lee TH, Ji YS, Park SW, Heo H. Retinal ganglion cell and axonal loss in optic neuritis: risk factors and visual functions. Eye. 2017;31(3):467–74.Search in Google Scholar
[4] Sun Q, Sun M, Zhang Y, Wang S, Bai W, Wei S, et al. Clinical characteristics of methanol-induced optic neuropathy: Correlation between aetiology and clinical findings. J Ophthalmol. 2022;2022:4671671.Search in Google Scholar
[5] Zhang W, Sun X-Q, Peng X-Y. Macular ganglion cell complex injury in different stages of anterior ischemic optic neuropathy. World J Clin Cases. 2021;9(21):5830–9.Search in Google Scholar
[6] Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang J, et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler. 2020;26(11):1360–71.Search in Google Scholar
[7] Lee GI, Kim J, Lee D, Park KA, Oh SY, Kong DS, et al. Ganglion cell inner plexiform layer thickness measured by optical coherence tomography to predict visual outcome in chiasmal compression. Sci Rep. 2022;12(1):14826.Search in Google Scholar
[8] De Dompablo E, Garcia-Montesinos J, Munoz-Negrete FJ, Rebolleda G. Ganglion cell analysis at acute episode of nonarteritic anterior ischemic optic neuropathy to predict irreversible damage. A prospective study. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1793–800.Search in Google Scholar
[9] Syc SB, Saidha S, Newsome SD, Ratchford JN, Levy M, Ford E, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012;135(Pt 2):521–33.Search in Google Scholar
[10] Henderson AP, Altmann DR, Trip AS, Kallis C, Jones SJ, Schlottmann PG, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain. 2010;133(9):2592–602.Search in Google Scholar
[11] Pietroboni AM, Carandini T, Dell’Arti L, Bovis F, Colombi A, De Riz MA, et al. Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurol Sci. 2020;41(11):3175–83.Search in Google Scholar
[12] Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Green AJ. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016;263(7):1323–31.Search in Google Scholar
[13] Fard MA, Golizadeh A, Yadegari S, Ghahvehchian H, Subramanian P, Ritch R. Photoreceptor outer nuclear layer thickness changes in optic neuritis follow up. Mult Scler Relat Disord. 2020;39:101905.Search in Google Scholar
[14] Kupersmith MJ, Garvin MK, Wang JK, Durbin M, Kardon R. Retinal ganglion cell layer thinning within one month of presentation for optic neuritis. Mult Scler. 2016;22(5):641–8.Search in Google Scholar
[15] Huang Y, Zhou L, ZhangBao J, Cai T, Wang B, Li X, et al. Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Br J Ophthalmol. 2019;103(6):789–96.Search in Google Scholar
[16] Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, Farrell SK, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain. 2011;134(Pt 2):518–33.Search in Google Scholar
[17] Higashiyama T, Ichiyama Y, Muraki S, Nishida Y, Ohji M. Optical coherence tomography angiography in a patient with optic atrophy after non-arteritic anterior ischaemic optic neuropathy. Neuroophthalmology. 2016;40(3):146–9.Search in Google Scholar
[18] Kwapong WR, Peng C, He Z, Zhuang X, Shen M, Lu F. Altered macular microvasculature in neuromyelitis optica spectrum disorders. Am J Ophthalmol. 2018;192:47–55.Search in Google Scholar
[19] Walter SD, Ishikawa H, Galetta KM, Sakai RE, Balcer LJ. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. 2012;119(6):1250–7.Search in Google Scholar
[20] Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, Takahashi T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28–33.Search in Google Scholar
[21] Wu Y, Zhong L, Geng J. Visual impairment in neuromyelitis optica spectrum disorders (NMOSD). J Chem Neuroanat. 2019;97:66–70.Search in Google Scholar
[22] Peng CX, Li HY, Wang W, Wang JQ, Wang L, Xu QG, et al. Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. Br J Ophthalmol. 2017;101(8):1032–7.Search in Google Scholar
© 2024 the author(s), published by De Gruyter
This work is licensed under the Creative Commons Attribution 4.0 International License.
